We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ridgeback Biotherapeutics in July will launch two phase 2 trials of its investigational antiviral EIDD-2801 as a potential COVID-19 treatment. Read More
A European Union-backed research consortium has identified raloxifene, an osteoporosis drug, as a possible treatment for mildly symptomatic COVID-19 patients. Read More
Chinese drugmaker Clover Biopharmaceuticals has dosed the first participants in a phase 1 trial of its COVID-19 vaccine candidate, an Australian study that’s also evaluating two adjuvants contributed by its research partners. Read More
The WHO said this decision does not apply to the use or evaluation of hydroxychloroquine as a prophylaxis treatment in people exposed to COVID-19. Read More
A majority of European clinical trials of COVID-19 drugs are being run by universities and companies who either lack experience or have a poor track record in uploading their results to the EU’s trial database, which could lead to wasted research, according to a new report. Read More
A small study of early COVID-19 patients in Italy showed Roche’s Actemra (tocilizumab) provided no benefit, the Italian Medicines Agency (AIFA) said. Read More